Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Botanix Pharmaceuticals Limited ( (AU:BOT) ).
Botanix Pharmaceuticals Ltd has applied for quotation on the ASX of 1,771,429 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The additional shares, issued on 20 January 2026, will modestly increase the company’s free float and share capital base, potentially improving liquidity for investors and reflecting ongoing utilisation of equity-linked instruments in its capital structure.
The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is an Australia-listed biotechnology company operating in the pharmaceuticals industry under the ASX code BOT. The company focuses on developing and commercialising therapeutic products, leveraging clinical-stage assets in dermatology and other medical indications to address unmet patient needs in key healthcare markets.
Average Trading Volume: 5,352,388
Technical Sentiment Signal: Sell
Current Market Cap: A$265.7M
See more data about BOT stock on TipRanks’ Stock Analysis page.